| Inovio Biomedical Corporation |
|
|
11494 Sorrento Valley Rd.
San Diego, CA 92121-1318 USA
phone:
(858) 597-6006
fax:
858-597-0451 |
| Symbol |
INO |
| Exchange |
AMEX |
| Founded |
1983 |
| Employees |
35 |
|
|
 www.genetronics.com |
|
| Research Sector |
Medical Devices & Tech |
|
|
| Summary Description |
| Medical devices and drug combinations for cancer therapy.
|
|
| Management |
| Avtar Dhillon, M.D., President and Chief Executive Officer; Robert Goodenow, Ph.D., VP, Corporate Development; Paul M. Goldfarb M.D., F.A.C.S., Department of Surgery, University of California, San Diego, San Diego, CA, Advisor to all Programs; Peter Kies, Chief Financial Officer; Dietmar Rabussay, Ph.D., VP, Research and Development; Arlene A. Forastiere, M.D., Professor of Oncology at the Johns Hopkins Oncology Center; Hubert T. Greenway, M.D., CEO Emeritus, Scripps Clinic, Chairman of Mohs / Dermatology Division; John Thompson, Professor, Head, Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Australia; Daniel Von Hoff, M.D. F.A.C.P., Professor of Medicine, Molecular and Cellular Biology and Pathology, and Director of the Arizona Cancer Center at The University of Arizona in Tucson; Robert S. Warren, M.D., Professor of Surgery, UCSF; Chief, Surgical Oncology Program |
|
|
|
|
| Keywords |
| electroporation, dna, therapy, cancer, breast, cancer, pancreatic, cancer, head, neck, cancer, skin, carcinoma, Urology, prostate, urinary, bladder, erectile, oncology, gene, therapy
|
|
|
|
|
Description |
| Inovio Biomedical Corporation, formerly Genetronics Biomedical Corporation, is a biomedical company developing medical therapies for cancer using its Electroporation Therapy (EPT) technology. The therapy aims at selective killing of cancer cells and local ablation of solid tumors, while preserving healthy tissue. |
|
| Products / Services |
Inovio's lead product, MedPulser Electroporation Therapy System, is in premarketing studies for head and neck cancer, and skin cancer in Europe, as well as in phase III pivotal study for recurrent head and neck cancer in the United States. The system delivers electrical pulses to tumors injected with the generic drug bleomycin. The company is also developing devices for the delivery of DNA for vaccinations and gene therapy.
|
|
| Technology / Differentiation |
| Electroporation Therapy utilizes electroporation in the delivery of drugs and genes directly into human cells. Briefly applying an electric field to a living cell causes a transient permeability in the cell's outer membrane. This permeation is manifest by the appearance of pores across the membrane. After the field is discontinued, the pores close within minutes without significant damage to the exposed cells and with the therapeutic molecules trapped inside the target cells. |
|
| Market / Customers |
Cancer is the second leading cause of death in the US, topped only by heart disease. Solid tumors, many suited to localized treatment using Inovio's electrochemical tumor ablation therapy, represent over 85% of all cancers. With 87% of cancer deaths in people aged 55+, the aging developed-world population suggests increasing cancer cases and deaths.
|
|
| Competitors / Substitutes / Alternatives |
Alkermes Inc., and IOMED Inc.
|
|
| Strategy |
Inovio has partnerships primarily with Merck & Co., Vical Inc., the University of South Florida Research Foundation, Inc. and Chiron.
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
